PATENT CLAIM ANALYSIS

Application Number: 15865339
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "019000"]

Abstract:
A phosphodiesterase type III (PDE III) inhibitor or Ca 2+ -sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.

Claim (Index 14):
The method of  claim 8 , wherein the anti-arrhythmic agent is selected from the group consisting of amiodarone, betrylium, disopyramide, dofetilide, flecamide, ibutilide, mexiletine, tocainide, procainamide, propafenone, quinidine and sotalol, and combinations thereof.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 86.0
- Lexical Diversity: 1.30303
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14175175', '11087465', '12482481', '13832292', '14401943']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8016355669253719
- 35 USC 102 Novelty (BERT): 0.5814823978604164
- Combined Prediction Score: 0.7796202500188764
- Mean Citation Score: 413.59645200000006
- Max Citation Score: 481.5739
- Similarity Product: 410.99571449570647

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test